[go: up one dir, main page]

ECSP17015154A - Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo - Google Patents

Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo

Info

Publication number
ECSP17015154A
ECSP17015154A ECIEPI201715154A ECPI201715154A ECSP17015154A EC SP17015154 A ECSP17015154 A EC SP17015154A EC IEPI201715154 A ECIEPI201715154 A EC IEPI201715154A EC PI201715154 A ECPI201715154 A EC PI201715154A EC SP17015154 A ECSP17015154 A EC SP17015154A
Authority
EC
Ecuador
Prior art keywords
patients
udenafilo
compositions
methods
improve myocardial
Prior art date
Application number
ECIEPI201715154A
Other languages
English (en)
Inventor
James L Yeager
Original Assignee
Han Sung T I Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Han Sung T I Co Ltd filed Critical Han Sung T I Co Ltd
Publication of ECSP17015154A publication Critical patent/ECSP17015154A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere generalmente al campo del uso de udenafilo o una sal farmacéuticamente aceptable del mismo en pacientes que se han sometido a la operación de Fontan.
ECIEPI201715154A 2014-08-12 2017-03-10 Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo ECSP17015154A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462036506P 2014-08-12 2014-08-12
US201562186132P 2015-06-29 2015-06-29

Publications (1)

Publication Number Publication Date
ECSP17015154A true ECSP17015154A (es) 2017-05-31

Family

ID=55301323

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201715154A ECSP17015154A (es) 2014-08-12 2017-03-10 Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo

Country Status (24)

Country Link
US (7) US10137128B2 (es)
EP (2) EP4342531A3 (es)
JP (5) JP2017524705A (es)
KR (4) KR20210038708A (es)
CN (2) CN107073001A (es)
AU (3) AU2015302271B2 (es)
BR (1) BR112017002675A2 (es)
CA (5) CA3128697C (es)
CL (1) CL2017000329A1 (es)
CO (1) CO2017000271A2 (es)
DO (1) DOP2017000014A (es)
EA (1) EA201692518A3 (es)
EC (1) ECSP17015154A (es)
IL (2) IL285193B2 (es)
MX (1) MX390977B (es)
MY (1) MY200278A (es)
NZ (1) NZ765800A (es)
PE (1) PE20170469A1 (es)
PH (1) PH12017500120A1 (es)
SG (2) SG10202100300RA (es)
TN (1) TN2017000029A1 (es)
TW (5) TW202224685A (es)
UA (1) UA120514C2 (es)
WO (1) WO2016025100A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY200278A (en) * 2014-08-12 2023-12-18 Mezzion Pharma Co Ltd Methods of improving exercise capacity in fontan patients using udenafil compositions
US20170112857A1 (en) * 2015-10-27 2017-04-27 New Haven Pharmaceuticals, Inc. Extended Release Aspirin
KR102249155B1 (ko) 2019-07-26 2021-05-07 주식회사 코아팜바이오 유데나필을 함유하는 약제학적 조성물
AU2020356193A1 (en) * 2019-09-24 2022-05-19 Children's Hospital Of Philadelphia Methods of improving exercise performance, single ventricular performance, and myocardial performance index (MPI) in single ventricle heart disease, using udenafil compositions
CA3229274A1 (en) 2021-08-13 2023-02-16 Mezzion Pharma Co., Ltd. Methods and compositions for treating fibrotic liver conditions, using udenafil compositions
JP2025504706A (ja) 2021-12-20 2025-02-17 メジオン ファーマ カンパニー リミテッド 運動機能を改善する方法および組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100353014B1 (ko) 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
US20050272741A1 (en) * 2004-01-16 2005-12-08 Jack Rychik Novel methods of treatment for Fontan patients with protein losing enteropathy
SG166106A1 (en) 2005-09-29 2010-11-29 Bayer Schering Pharma Ag Pde inhibitors and combinations thereof for the treatment of urological disorders
NL2000291C2 (nl) 2005-11-10 2009-02-17 Pfizer Prod Inc 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
WO2007113243A2 (en) 2006-03-31 2007-10-11 Investigación Y Clínica Andrológicas S.L. Use of pde 5 inhibitors for the treatment of overactive bladder
KR100792126B1 (ko) 2006-04-04 2008-01-04 동아제약주식회사 피라졸로피리미디논 화합물을 유효성분으로 함유하는전립선 비대증 예방 및 치료제
KR101002490B1 (ko) 2007-06-09 2010-12-17 동아제약주식회사 유데나필을 유효성분으로 함유하는 만성 심부전증 치료용약학적 조성물
KR20100029762A (ko) 2007-06-13 2010-03-17 바이엘 쉐링 파마 악티엔게젤샤프트 청력 장애 치료용 ｐｄｅ 억제제
KR101004205B1 (ko) 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
KR101071877B1 (ko) * 2009-02-18 2011-10-10 동아제약주식회사 유데나필 산부가염, 그의 제조방법 및 이를 포함하는 약학적 조성물
EP2512479B1 (en) 2009-12-18 2016-03-30 Exodos Life Sciences Limited Partnership Compositions for treating peripheral vascular disease
CN102970965A (zh) 2010-04-05 2013-03-13 Sk化学公司 含有pde5抑制剂的减少皮肤皱纹的合成物
JP5883687B2 (ja) 2011-03-09 2016-03-15 第一三共ヘルスケア株式会社 Ｐｄｅ５阻害剤含有医薬組成物
KR101383430B1 (ko) 2012-01-26 2014-04-08 광동제약 주식회사 새로운 조합의 구강내 속붕해 필름형성 조성물 및 ｐｄｅ５ 저해제가 함유된 구강내 속붕해 필름제제
CN108452311A (zh) 2012-11-13 2018-08-28 纽斯尔特科学公司 用于增强能量代谢的组合物和方法
MY200278A (en) 2014-08-12 2023-12-18 Mezzion Pharma Co Ltd Methods of improving exercise capacity in fontan patients using udenafil compositions

Also Published As

Publication number Publication date
NZ765796A (en) 2024-02-23
IL285193B1 (en) 2023-07-01
MX2017001396A (es) 2017-12-04
US20190030038A1 (en) 2019-01-31
CA3128705A1 (en) 2016-02-18
US20160045510A1 (en) 2016-02-18
JP2017524705A (ja) 2017-08-31
CA2954183C (en) 2023-10-31
TW202118491A (zh) 2021-05-16
AU2019203706A1 (en) 2019-06-20
EP3180008A2 (en) 2017-06-21
IL250547B (en) 2021-07-29
EA201692518A3 (ru) 2017-11-30
CA3128691A1 (en) 2016-02-18
JP2025032254A (ja) 2025-03-11
US20230095034A1 (en) 2023-03-30
US10137128B2 (en) 2018-11-27
CA3128697A1 (en) 2016-02-18
CA2954183A1 (en) 2016-02-18
BR112017002675A2 (pt) 2017-12-12
TWI767153B (zh) 2022-06-11
NZ765800A (en) 2024-03-22
SG11201700060WA (en) 2017-02-27
CO2017000271A2 (es) 2017-05-31
AU2021202212A1 (en) 2021-05-06
TW202002982A (zh) 2020-01-16
EP4342531A2 (en) 2024-03-27
JP2019077726A (ja) 2019-05-23
US12048701B2 (en) 2024-07-30
EP4342531A3 (en) 2024-06-26
IL285193A (en) 2021-08-31
US20250064817A1 (en) 2025-02-27
US20190030037A1 (en) 2019-01-31
CN118436655A (zh) 2024-08-06
US20180169103A1 (en) 2018-06-21
US20220047601A1 (en) 2022-02-17
EA201692518A2 (ru) 2017-07-31
IL250547A0 (en) 2017-03-30
EP3180008A4 (en) 2018-01-24
JP2021091721A (ja) 2021-06-17
CA3128691C (en) 2025-10-07
PH12017500120A1 (en) 2017-05-29
TWI730944B (zh) 2021-06-21
CL2017000329A1 (es) 2017-11-03
CA3128697C (en) 2025-10-07
KR20210038708A (ko) 2021-04-07
AU2015302271B2 (en) 2019-02-28
JP2024020187A (ja) 2024-02-14
MX390977B (es) 2025-03-21
IL285193B2 (en) 2023-11-01
KR20240122604A (ko) 2024-08-12
US10653698B2 (en) 2020-05-19
EP3180008B1 (en) 2023-11-29
CA3128680A1 (en) 2016-02-18
KR20170066334A (ko) 2017-06-14
TW201617080A (zh) 2016-05-16
DOP2017000014A (es) 2017-06-30
PE20170469A1 (es) 2017-04-21
KR20230116098A (ko) 2023-08-03
SG10202100300RA (en) 2021-02-25
TN2017000029A1 (en) 2018-07-04
MY200278A (en) 2023-12-18
TW202400176A (zh) 2024-01-01
CN107073001A (zh) 2017-08-18
AU2015302271A1 (en) 2017-01-12
WO2016025100A2 (en) 2016-02-18
UA120514C2 (uk) 2019-12-26
CA3128680C (en) 2025-10-07
TW202224685A (zh) 2022-07-01
TWI860641B (zh) 2024-11-01
CA3128705C (en) 2025-10-07

Similar Documents

Publication Publication Date Title
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CR20140318A (es) Composiciones intranasales de dexmedetomidina y métodos de uso de ellas
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
ECSP17015154A (es) Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo
CO2017003279A2 (es) Compuestos y composiciones farmacéuticamente aceptables de los mismos, eficaces como inhibidores de mk2
MX2017001279A (es) Usos y composiciones de la flagelina.
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
CO2018012180A2 (es) Métodos de tratamiento para enfermedades colestásicas y fibróticas
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
BR112017015159A2 (pt) preparação e uso de produtos plaquetários
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
CR20180328A (es) Compuestos de isoindol
MX389026B (es) Una composicion farmaceutica y el uso de la misma.
MX2017003469A (es) Inhibidores macrociclicos de cinasa rip2.
CR20160369A (es) Composiciones para uso en el tratamiento de afecciones alérgicas
MX376504B (es) Composiciones para el tratamiento de enfermedades renales y/o hepaticas.
CR20150352A (es) Nuevas composiciones antifúngicidas
MX2017014998A (es) Uso de hidroxido de potasio en el tratamiento de la queratosis actinica.
CL2011001916A1 (es) Uso de ezatiostat o una sal de el para el tratamiento del sindrome mielodisplasico; composicion farmaceutica que comprende a dicho compuesto ademas de lenalidomida; combinacion farmaceutica; kit farmaceutico.